NATHANIEL M. BRAMAN ET AL: "Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI", BREAST CANCER RESEARCH, vol. 19, no. 1, 18 May 2017 (2017-05-18), XP055506030, DOI: 10.1186/s13058-017-0846-1 (B1)

PATRICK GROSSMANN ET AL: "Defining the biological basis of radiomic phenotypes in lung cancer", LIFE 2017;6:E23421, 21 July 2017 (2017-07-21), pages 1 - 48, XP055506071, Retrieved from the Internet <URL:https://doi.org/10.7554/eLife.23421.001> [retrieved on 20180911], DOI: 10.7554/eLife.23421 (B1)

Q WEN ET AL: "Radiomic CT Features for Evaluation of PD-L1, CD8+TILs and Foxp3+TILs Expression Status in Patients with Stage I NSCLC", INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY, VOLUME 99, ISSUE 2, SUPPLEMENT,, 1 October 2017 (2017-10-01), pages E738 - E738, XP055506121, Retrieved from the Internet <URL:https://www.redjournal.org/article/S0360-3016(17)33431-4/fulltext> [retrieved on 20180911] (B1)

WO-A1-2016/083791 (B1)

ROGER SUN ET AL: "A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study", THE LANCET ONCOLOGY, VOLUME 19, ISSUE 9, SEPTEMBER 2018, 1 September 2018 (2018-09-01), pages 1180 - 1191, XP055505301, Retrieved from the Internet <URL:https://reader.elsevier.com/reader/sd/0903C829240DE915841D582E9F4CF731F114E5EAEB4865030EDAE1AB88C85AC2C671936084BAD06E6D1DDAE8476099DD> [retrieved on 20180906] (B1)

TOKITO TAKAAKI ET AL: "Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy", EUROPEAN JOURNAL OF CANCER, ELSEVIER, AMSTERDAM, NL, vol. 55, 6 January 2016 (2016-01-06), pages 7 - 14, XP029428431, ISSN: 0959-8049, DOI: 10.1016/J.EJCA.2015.11.020 (B1)

US-A1- 2017 193 175 (B1)

R SUN ET AL: "A novel radiomic based imaging tool to monitor tumor lymphocyte infiltration and outcome of patients treated by anti-PD-1/PD-L1", ANNALS OF ONCOLOGY, VOLUME 28, ISSUE SUPPL.5, 1 September 2017 (2017-09-01), pages 1 - 1, XP055506096, Retrieved from the Internet <URL:https://academic.oup.com/annonc/article/28/suppl_5/mdx390.004/4109674> [retrieved on 20180911] (B1)